| Date | Time | Source | Headline | Symbol | Company |
| 09/26/2024 | 4:45PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALT | Altimmune Inc |
| 09/10/2024 | 1:09PM | GlobeNewswire Inc. | CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
| 09/10/2024 | 7:45AM | GlobeNewswire Inc. | Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
| 09/03/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes | NASDAQ:ALT | Altimmune Inc |
| 08/20/2024 | 6:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
| 08/15/2024 | 4:14PM | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:ALT | Altimmune Inc |
| 08/15/2024 | 4:08PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:ALT | Altimmune Inc |
| 08/15/2024 | 4:03PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALT | Altimmune Inc |
| 08/08/2024 | 4:07PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ALT | Altimmune Inc |
| 08/08/2024 | 7:04AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALT | Altimmune Inc |
| 08/08/2024 | 7:00AM | GlobeNewswire Inc. | Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:ALT | Altimmune Inc |
| 08/07/2024 | 7:00AM | GlobeNewswire Inc. | CytoSorbents to Report Second Quarter 2024 Operating and Financial Results | NASDAQ:ALT | Altimmune Inc |
| 08/01/2024 | 5:47PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
| 08/01/2024 | 5:45PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
| 08/01/2024 | 5:43PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
| 08/01/2024 | 5:40PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
| 08/01/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 | NASDAQ:ALT | Altimmune Inc |
| 07/25/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology | NASDAQ:ALT | Altimmune Inc |
| 07/03/2024 | 5:45AM | PR Newswire (US) | Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm | NASDAQ:ALT | Altimmune Inc |
| 07/02/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Participate at Leerink Partners Therapeutics Forum | NASDAQ:ALT | Altimmune Inc |
| 06/28/2024 | 5:45AM | PR Newswire (US) | Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm | NASDAQ:ALT | Altimmune Inc |
| 06/26/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt | NASDAQ:ALT | Altimmune Inc |
| 06/25/2024 | 5:45AM | PR Newswire (US) | Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT | NASDAQ:ALT | Altimmune Inc |
| 06/23/2024 | 1:45PM | GlobeNewswire Inc. | Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
| 06/22/2024 | 4:45PM | GlobeNewswire Inc. | Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
| 06/20/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways | NASDAQ:ALT | Altimmune Inc |
| 06/20/2024 | 5:45AM | PR Newswire (US) | Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT | NASDAQ:ALT | Altimmune Inc |
| 06/18/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions | NASDAQ:ALT | Altimmune Inc |
| 06/17/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT | NASDAQ:ALT | Altimmune Inc |
| 06/10/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT | NASDAQ:ALT | Altimmune Inc |